Send the following on WhatsApp
Continue to Chathttps://www.zonebourse.com/cours/action/INFLARX-N-V-38607083/actualite/InflaRx-N-V-annonce-le-dosage-du-premier-patient-dans-l-etude-de-phase-III-sur-le-vilobelimab-dan-45249955/?utm_source=whatsapp&utm_medium=social&utm_campaign=share